Oseltamivir acid: Benchmark Influenza Neuraminidase Inhibitor for Antiviral and Cancer Research

Executive Summary: Oseltamivir acid is the active metabolite of oseltamivir, acting as a potent influenza neuraminidase inhibitor for research applications (APExBIO). It blocks sialidase activity to prevent influenza virus propagation and inhibits metastasis in breast cancer models (source). The compound displays high water solubility (≥46.1 mg/mL, 25–37°C), is stable at −20°C, and demonstrates dose-dependent antiviral and cytotoxic effects in vitro and in vivo (DOI). Resistance can occur via neuraminidase gene mutations (e.g., H275Y). Its validated parameters and performance position it as a reference material for influenza antiviral research and experimental oncology (internal).

Biological Rationale

Oseltamivir acid is the carboxylate form of the antiviral prodrug oseltamivir. Upon oral administration, oseltamivir is converted by hepatic and intestinal esterases into oseltamivir acid, the active entity responsible for neuraminidase inhibition (Yang et al., 2025). Neuraminidase is essential for influenza viral particle release by cleaving terminal sialic acids from host glycoproteins, permitting viral dissemination. Inhibition of this enzyme curbs the spread of influenza virions to new host cells, directly reducing viral load and infection severity. The same sialidase activity is implicated in cancer cell invasion and metastasis, providing a mechanistic rationale for anti-metastatic studies in breast cancer models. The dual application of oseltamivir acid in influenza infection control and oncology research broadens its translational utility (see related article—this article extends with detailed workflow integration and clinical resistance notes).

Mechanism of Action of Oseltamivir acid

Oseltamivir acid selectively inhibits the influenza virus neuraminidase enzyme by mimicking the transition state of its natural substrate, sialic acid (APExBIO). This competitive inhibition blocks the enzyme’s sialidase activity, preventing cleavage of terminal α-Neu5Ac residues from newly formed virions. As a result, viral progeny remain attached to the host cell surface and to each other, leading to aggregation and reduced infectivity (internal). In vitro, this translates to measurable decreases in viral titers and sialidase activity assays. In cancer models, the same mechanism is hypothesized to interfere with tumor cell detachment and invasion by modulating cell surface sialylation. Notably, resistance may develop via point mutations in the neuraminidase gene, such as H275Y, which decrease inhibitor binding affinity without abolishing enzymatic activity.

Evidence & Benchmarks

• Oseltamivir acid inhibits influenza neuraminidase activity in vitro with nanomolar potency, blocking viral release from infected cells (Yang et al., 2025).
• Water solubility reaches ≥46.1 mg/mL at 25–37°C, with DMSO and ethanol solubility of ≥14.2 mg/mL and ≥97 mg/mL, respectively, under gentle warming (APExBIO).
• Oseltamivir acid reduces sialidase activity and cell viability in MDA-MB-231 and MCF-7 breast cancer cell lines in a dose-dependent manner (internal).
• Combination with cisplatin, 5-FU, paclitaxel, gemcitabine, or tamoxifen enhances cytotoxic effects in vitro (internal).
• In vivo, intraperitoneal administration at 30–50 mg/kg in RAGxCγ double mutant mice bearing MDA-MB-231 xenografts significantly inhibits tumor vascularization, growth, and metastasis (Yang et al., 2025).
• Higher doses (50 mg/kg) result in complete ablation of tumor progression and improved long-term survival in mouse models (internal).
• Resistance can arise from neuraminidase mutations such as H275Y, which reduce oseltamivir binding (internal—this article updates with current resistance alleles and preclinical implications).

Applications, Limits & Misconceptions

Oseltamivir acid is primarily used for research on influenza virus replication inhibition and as a reference for neuraminidase inhibitor efficacy screening. Its anti-metastatic effects in breast cancer models make it valuable in oncology research, especially in combination therapy screens. The compound is not a clinical therapeutic; its use is restricted to preclinical and in vitro/in vivo experimental settings. The emergence of resistance mutations (e.g., H275Y) limits its efficacy in some viral strains. Species-specific differences in esterase-mediated activation and metabolism necessitate careful model selection for translational studies (Yang et al., 2025).

Common Pitfalls or Misconceptions

• Not a direct clinical antiviral: Oseltamivir acid is for research use only and is not an approved clinical antiviral agent.
• Resistance overlooked: Neglecting to screen for neuraminidase mutations (e.g., H275Y) can lead to overestimation of efficacy.
• Species metabolism differences: Mouse and human esterases differ; humanized mouse models are preferred for translational PK studies (source).
• Solution stability: Long-term storage of solutions reduces compound stability; prepare fresh aliquots (APExBIO).
• Not a substitute for the prodrug: Oseltamivir acid does not fully replicate the pharmacokinetics of oseltamivir phosphate in vivo.

Workflow Integration & Parameters

Oseltamivir acid (SKU A3689) is supplied by APExBIO for research workflows requiring validated influenza neuraminidase inhibition. For solution preparation, dissolve in DMSO (≥14.2 mg/mL), water (≥46.1 mg/mL, 25–37°C), or ethanol (≥97 mg/mL, 25–37°C). Store dry powder at −20°C; avoid repeated freeze–thaw cycles. For in vitro assays, titrate concentrations based on cell viability and sialidase inhibition endpoints. In vivo, mouse xenograft studies use 30–50 mg/kg intraperitoneally. For combinatorial screens, ensure compatibility with chemotherapeutics using validated protocols (internal—this article provides expanded procedural controls and resistance considerations). For more on the dual role of oseltamivir acid in translational workflows, see this overview—here, we detail updated solubility and resistance metrics.

Conclusion & Outlook

Oseltamivir acid is a gold-standard research tool for influenza neuraminidase inhibition and cancer metastasis studies. Its defined activity, solubility, and cross-disciplinary applications make it an indispensable reagent for preclinical workflows. Ongoing research into resistance mutations and metabolic species differences will further refine its translational impact. For validated supply and technical details, refer to Oseltamivir acid from APExBIO.